ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Has Consensus Price Target of $4.60

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $4.60.

Separately, Weiss Ratings upgraded shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th.

ALX Oncology Trading Down 8.3%

Shares of NASDAQ:ALXO opened at $1.11 on Friday. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. ALX Oncology has a 12-month low of $1.05 and a 12-month high of $2.66. The business has a 50 day moving average of $1.82 and a two-hundred day moving average of $1.86. The company has a market capitalization of $153.49 million, a PE ratio of -0.98 and a beta of 0.47.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, analysts forecast that ALX Oncology will post -0.59 EPS for the current year.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds have recently bought and sold shares of ALXO. Squarepoint Ops LLC acquired a new position in shares of ALX Oncology during the 2nd quarter worth approximately $97,000. AXQ Capital LP purchased a new position in shares of ALX Oncology during the 2nd quarter valued at approximately $84,000. Nantahala Capital Management LLC acquired a new stake in ALX Oncology in the 2nd quarter valued at $1,552,500. Beacon Pointe Advisors LLC acquired a new stake in ALX Oncology in the 2nd quarter valued at $26,000. Finally, venBio Partners LLC purchased a new stake in ALX Oncology in the 2nd quarter worth $26,671,201. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on developing therapies that activate the immune system to fight cancer. The company’s research is centered on the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid detection and destruction by immune cells.

Its lead investigational product is evorpacept, also known as ALX148, a protein therapeutic designed to block CD47 while limiting binding to red blood cells. Evorpacept is being evaluated in combination with other cancer treatments across several potential indications, including hematologic malignancies and solid tumors.